Revenue (Disaggregation of Revenue by Product) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Revenue	$ 6,488.0	$ 6,740.1	$ 14,298.0	$ 13,545.7
U.S.
Disaggregation of Revenue [Line Items]
Revenue	3,934.8	3,704.2	9,109.4	7,645.5
Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,553.3	3,035.9	5,188.7	5,900.2
Diabetes
Disaggregation of Revenue [Line Items]
Revenue	3,438.2	3,175.5	6,826.3	6,286.6
Diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenue	2,292.2	2,079.8	4,568.7	4,141.0
Diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,146.0	1,095.7	2,257.6	2,145.5
Trulicity®
Disaggregation of Revenue [Line Items]
Revenue	1,911.9	1,535.6	3,653.2	2,988.1
Trulicity® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	1,430.1	1,147.6	2,744.1	2,264.3
Trulicity® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	481.7	388.0	909.1	723.7
Jardiance
Disaggregation of Revenue [Line Items]
Revenue	461.0	356.5	880.4	668.5
Jardiance | U.S.
Disaggregation of Revenue [Line Items]
Revenue	250.7	194.4	480.4	345.6
Jardiance | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	210.3	162.1	400.0	322.9
Humalog®
Disaggregation of Revenue [Line Items]
Revenue	447.1	607.6	1,065.3	1,224.6
Humalog® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	238.8	329.1	607.7	661.7
Humalog® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	208.3	278.6	457.6	562.9
Humulin®
Disaggregation of Revenue [Line Items]
Revenue	274.0	315.3	547.2	637.0
Humulin® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	202.3	221.1	392.8	440.1
Humulin® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	71.7	94.3	154.5	196.9
Basaglar®
Disaggregation of Revenue [Line Items]
Revenue	174.2	210.7	365.7	457.3
Basaglar® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	95.8	133.4	215.1	308.6
Basaglar® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	78.4	77.3	150.6	148.7
Other diabetes
Disaggregation of Revenue [Line Items]
Revenue	170.0	149.8	314.5	311.1
Other diabetes | U.S.
Disaggregation of Revenue [Line Items]
Revenue	74.5	54.2	128.6	120.7
Other diabetes | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	95.6	95.4	185.8	190.4
Oncology
Disaggregation of Revenue [Line Items]
Revenue	1,368.7	1,554.0	2,721.7	2,926.3
Oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	819.0	828.3	1,602.7	1,470.8
Oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	549.8	725.7	1,119.0	1,455.4
Verzenio®
Disaggregation of Revenue [Line Items]
Revenue	588.5	341.3	1,057.9	610.3
Verzenio® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	384.3	209.7	685.7	382.5
Verzenio® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	204.2	131.6	372.1	227.8
Cyramza®
Disaggregation of Revenue [Line Items]
Revenue	231.3	268.7	461.5	509.2
Cyramza® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	92.6	101.4	171.8	181.5
Cyramza® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	138.6	167.3	289.7	327.7
Alimta®
Disaggregation of Revenue [Line Items]
Revenue	227.7	610.6	571.7	1,169.6
Alimta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	171.7	353.5	425.9	614.6
Alimta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	56.1	257.1	145.8	554.9
Erbitux®
Disaggregation of Revenue [Line Items]
Revenue	140.8	147.0	263.4	269.4
Erbitux® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	125.1	135.8	234.7	243.7
Erbitux® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	15.7	11.2	28.7	25.7
Tyvyt®
Disaggregation of Revenue [Line Items]
Revenue	73.6	105.0	159.0	214.6
Tyvyt® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	0.0	0.0	0.0
Tyvyt® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	73.6	105.0	159.0	214.6
Other oncology
Disaggregation of Revenue [Line Items]
Revenue	106.8	81.4	208.2	153.2
Other oncology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	45.3	27.9	84.6	48.5
Other oncology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	61.6	53.5	123.7	104.7
Immunology
Disaggregation of Revenue [Line Items]
Revenue	796.5	785.4	1,544.6	1,399.3
Immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	422.0	422.4	800.5	707.1
Immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	374.5	363.1	744.1	692.2
Taltz®
Disaggregation of Revenue [Line Items]
Revenue	606.2	569.1	1,094.3	972.4
Taltz® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	411.6	399.8	718.8	649.4
Taltz® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	194.7	169.3	375.5	322.9
Olumiant®
Disaggregation of Revenue [Line Items]
Revenue	186.2	208.4	441.8	402.2
Olumiant® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	10.4	17.8	81.7	42.5
Olumiant® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	175.8	190.6	360.1	359.7
Other immunology
Disaggregation of Revenue [Line Items]
Revenue	4.0	7.9	8.5	24.7
Other immunology | U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	4.8	0.0	15.2
Other immunology | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	4.0	3.2	8.5	9.6
Neuroscience
Disaggregation of Revenue [Line Items]
Revenue	389.9	512.2	787.7	977.6
Neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	144.8	166.7	298.1	308.4
Neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	245.2	345.5	489.5	669.2
Emgality®
Disaggregation of Revenue [Line Items]
Revenue	157.5	156.3	306.7	275.7
Emgality® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	108.6	112.1	216.9	213.6
Emgality® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	48.9	44.2	89.8	62.2
Zyprexa®
Disaggregation of Revenue [Line Items]
Revenue	87.3	95.4	180.4	191.1
Zyprexa® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	8.7	8.4	18.3	15.3
Zyprexa® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	78.6	86.9	162.1	175.8
Cymbalta®
Disaggregation of Revenue [Line Items]
Revenue	75.5	175.6	156.6	352.3
Cymbalta® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	8.1	12.4	17.2	23.3
Cymbalta® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	67.4	163.3	139.4	328.9
Other neuroscience
Disaggregation of Revenue [Line Items]
Revenue	69.6	84.9	144.0	158.5
Other neuroscience | U.S.
Disaggregation of Revenue [Line Items]
Revenue	19.4	33.8	45.7	56.2
Other neuroscience | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	50.3	51.1	98.2	102.3
Other
Disaggregation of Revenue [Line Items]
Revenue	494.7	712.9	2,417.7	1,955.9
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	256.9	207.0	1,839.2	1,018.1
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	237.9	506.0	578.5	937.8
Cialis®
Disaggregation of Revenue [Line Items]
Revenue	147.0	281.0	364.7	407.8
Cialis® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	10.8	(5.2)	17.7	3.4
Cialis® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	136.2	286.3	347.0	404.4
Forteo®
Disaggregation of Revenue [Line Items]
Revenue	138.5	218.4	275.9	416.9
Forteo® | U.S.
Disaggregation of Revenue [Line Items]
Revenue	78.5	122.8	148.7	220.5
Forteo® | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	60.0	95.6	127.2	196.4
COVID-19 Antibodies
Disaggregation of Revenue [Line Items]
Revenue	129.1	148.9	1,598.9	959.1
COVID-19 Antibodies | U.S.
Disaggregation of Revenue [Line Items]
Revenue	129.1	83.4	1,584.3	734.0
COVID-19 Antibodies | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	0.0	65.7	14.7	225.1
Other
Disaggregation of Revenue [Line Items]
Revenue	80.1	64.6	178.2	172.1
Other | U.S.
Disaggregation of Revenue [Line Items]
Revenue	38.5	6.0	88.5	60.2
Other | Outside U.S.
Disaggregation of Revenue [Line Items]
Revenue	$ 41.7	$ 58.4	$ 89.6	$ 111.9